You are here

Article Text

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV208/#485 The clinical demand for pressurized intraperitoneal aerosol chemotherapy in south korea: an electronic survey-based study
Free
  1. EJ Lee1,
  2. SJ Park1,
  3. J Mun2,
  4. H Paik2,
  5. J Lee2,
  6. A Seol2,
  7. J Kim2,
  8. N Lee3,
  9. GW Yim4,
  10. S-H Shim5,
  11. HS Kim1 and
  12. S-J Chang6
  1. 1Seoul National University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of
  2. 2Seoul National University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of
  3. 3CHA Gangnam Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of
  4. 4Dongguk University Ilsan Hospital, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of
  5. 5Konkuk University School of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of
  6. 6Ajou University School of Medicine, Obstetrics and Gynecology, Suwon, Korea, Republic of

Abstract

Objectives Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is effective for treating solid tumors with peritoneal metastasis. However, PIPAC is not a standard treatment globally and is currently only used in the limited areas. Thus, we performed a survey of surgical oncologists related to PIPAC to evaluate the clinical desire for PIPAC in South Korea, one of the many countries where PIPAC has not yet been introduced.

Methods We performed an online survey of Korean surgical oncologists between November and December 2019. The questionnaire consisted of 20 questions related to PIPAC, which were divided into comprehensive inquiry (5 questions), procedure inquiry (13 questions), and cost inquiry (2 questions).

Results A total of 164 respondents answered the questionnaire. Among all respondents, 41.7–50% majoring in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma preferred PIPAC for the curative treatment of primary diseases, whereas 32.7–33.3% majoring in colorectal and hepatobiliary cancers chose PIPAC for the palliative treatment of recurrent diseases. Moreover, 66.7–95.2% of the respondents considered PIPAC appropriate for the cancers the specialized in. About 70% expected a treatment response of more than 50% through the repeated implementation of PIPAC under general anesthesia. Respondents also considered grade 1 or 2 minor surgical complications an acceptable risk. Finally, respondents considered the reasonable costs to purchase and implement PIPAC once at between 1,000,000–5,000,000 KRW.

Conclusions Although the treatment scope for applying PIPAC was different among Korean surgical oncologists, most of them expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.

https://doi.org/10.1136/ijgc-2021-IGCS.279

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.